泰吉利定对腹腔镜胃肠手术老年衰弱患者术后精神运动功能恢复的影响

注册号:

Registration number:

ChiCTR2600115893 

最近更新日期:

Date of Last Refreshed on:

2026-01-04 00:29:35 

注册时间:

Date of Registration:

2026-01-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

泰吉利定对腹腔镜胃肠手术老年衰弱患者术后精神运动功能恢复的影响

Public title:

Effects of Tegituridine on Postoperative Psychomotor Recovery in Elderly Frail Patients Undergoing Laparoscopic Gastrointestinal Surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

泰吉利定对腹腔镜胃肠手术老年衰弱患者术后精神运动功能恢复的影响

Scientific title:

Effects of Tegituridine on Postoperative Psychomotor Recovery in Elderly Frail Patients Undergoing Laparoscopic Gastrointestinal Surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王彬 

研究负责人:

王彬 

Applicant:

Wang Bin 

Study leader:

Wang Bin 

申请注册联系人电话:

Applicant telephone:

+86 132 9542 6246

研究负责人电话:

Study leader's
telephone:

+86 132 9542 6246

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wangbin328@sina.com

研究负责人电子邮件:

Study leader's E-mail:

wangbin328@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市市北区胶州路1号

研究负责人通讯地址:

山东省青岛市市北区胶州路1号

Applicant address:

No. 1, Jiaozhou Road, Shibei District, Qingdao City, Shandong Province

Study leader's address:

No. 1, Jiaozhou Road, Shibei District, Qingdao City, Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

266071

研究负责人邮政编码:

Study leader's postcode:

266071

申请人所在单位:

青岛市市立医院

Applicant's institution:

Qingdao Municipal Hospital

研究负责人所在单位:

青岛市市立医院

Affiliation of the Leader:

Qingdao Municipal Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-KY-021

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青岛市市立医院伦理委员会

Name of the ethic committee:

Ethics Committee of Qingdao Municipal Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-26 00:00:00

伦理委员会联系人:

王国安

Contact Name of the ethic committee:

Wang Guoan

伦理委员会联系地址:

山东省青岛市市北区胶州路1号

Contact Address of the ethic committee:

No. 1, Jiaozhou Road, Shibei District, Qingdao City, Shandong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 532 8278 9053

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛市市立医院

Primary sponsor:

Qingdao Municipal Hospital

研究实施负责(组长)单位地址:

山东省青岛市市北区胶州路1号

Primary sponsor's address:

No. 1, Jiaozhou Road, Shibei District, Qingdao City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

青岛

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛市市立医院

具体地址:

山东省青岛市市北区胶州路1号

Institution
hospital:

Qingdao Municipal Hospital

Address:

No. 1, Jiaozhou Road, Shibei District, Qingdao City, Shandong Province

经费或物资来源:

Source(s) of funding:

None

研究疾病:

术后精神运动功能恢复情况  

Target disease:

Postoperative Psychomotor Recovery

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

泰吉利定现已应用于治疗腹部手术后中重度疼痛,但泰吉利定对腹腔镜胃肠手术老年衰弱患者术后精神运动功能恢复的影响,尚无国际使用的报道,因此本研究可填补该领域的空白。  

Objectives of Study:

Tegituridine is now used for managing moderate-to-severe pain after abdominal surgery. However, its impact on postoperative psychomotor recovery in elderly frail patients undergoing laparoscopic gastrointestinal surgery remains unreported internationally. This study aims to address this knowledge gap.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)妊娠或哺乳期女性以及3个月内有生育计划者; (2)术前存在明显呼吸、循环功能障碍、血常规和血生化指标明显异常者; (3)有严重神经精神系统疾病者; (4)对泰吉利定等药物及其组分过敏或禁忌者; (5)长期(3个月以上)服用抗抑郁药、抗焦虑药或其他精神药物的; (6)不能理解或拒绝完成问卷; (7)无法获得知情同意者,或是研究者认为不宜参加此试验患者。

Exclusion criteria:

(1) Pregnant or lactating women and those who have a birth plan within 3 months; (2) Those with obvious respiratory and circulatory dysfunction, blood routine and blood biochemical indicators before surgery; (3) Those with severe neuropsychiatric diseases; (4) Patients with known hypersensitivity or contraindications to Tegituridine or any of its excipients; (5) Taking antidepressants, anxiolytics or other psychotropic drugs for a long time (more than 3 months); (6) Unable to understand or refuse to complete the questionnaire; (7) Patients who cannot obtain informed consent, or who are considered by the investigator to be inappropriate to participate in this trial.

研究实施时间:

Study execute time:

From 2026-01-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-01-04 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

泰吉利定组

样本量:

66

Group:

Tegituridine group

Sample size:

干预措施:

泰吉利定术后镇痛

干预措施代码:

Intervention:

Tegituridine for Postoperative Analgesia

Intervention code:

组别:

舒芬太尼组

样本量:

66

Group:

Sufentanil group

Sample size:

干预措施:

舒芬太尼术后镇痛

干预措施代码:

Intervention:

Sufentanil for Postoperative Analgesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

青岛 

Country:

China

Province:

Shandong

City:

Qingdao

单位(医院):

青岛市市立医院 

单位级别:

三甲 

Institution
hospital:

Qingdao Municipal Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后精神运动功能恢复

指标类型:

主要指标

Outcome:

Postoperative Psychomotor Recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后24h、48h疼痛VAS评分

指标类型:

次要指标

Outcome:

Pain VAS scores at 24 and 48 hours postoperatively

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后24h、48h并发症的发生率

指标类型:

次要指标

Outcome:

Incidence of postoperative complications at 24 and 48 hours.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后24h、48h术后恢复质量评分(Qor-15)

指标类型:

次要指标

Outcome:

Quality of Recovery-15 (QoR-15) scores at 24 and 48 hours postoperatively.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者住院时间

指标类型:

次要指标

Outcome:

Length of patient hospital stay.

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

使用后销毁  

说明

none

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由与本试验执行数据管理统计分析无关的统计学专家,在计算机上用SAS统计软件包,按试验组与对照组1:1的比例随机产生随机数字。本研究采用中央随机分层;

Randomization Procedure (please state who generates the random number sequence and by what method):

Random numbers were randomly generated by statistical experts who were not involved in the statistical analysis of data management in this study using the SAS statistical software package on a computer according to the ratio of 1:1 between the experimental group and the control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

指定一名研究协调员,负责保存和分发随机号码、准备药物以及研究人员之间的信息协调;指定 一名主治医师负责麻醉实施和记录术中信息;指定一名副主任药师负责术后给予研究药物和监测药物安全;由经过培训的随访者负责病人的随访;以上研究人员在研究期间互相不知道对方的研究结果;统计分析由青岛市市立医院麻醉科负责完成。

Blinding:

A research coordinator was designated to be responsible for preserving and distributing random numbers, preparing drugs, and coordinating information among researchers; a chief physician was appointed to be in charge of anesthesia implementation and recording intraoperative information; a deputy chief pharmacist was assigned to be responsible for administering study drugs postoperatively and monitoring drug safety; trained follow-up personnel were responsible for patient follow-up. The above researchers were unaware of each other's research results during the study period. Statistical analysis was completed by the Department of Anesthesiology of Qingdao Municipal Hospital.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-01-04 00:29:30